Oxaprozin

• Description :

  Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].

• CAS Number :

  [21256-18-8]

• Product Name Alternative :

  Oxaprozinum; Wy21743

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Akt; Apoptosis; COX; IKK; NF-κB

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Immunology/Inflammation; NF-κB; PI3K/Akt/mTOR

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Oxaprozin.html

• Purity :

  99.94

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  O=C(O)CCC1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)O1

• Molecular Formula :

  C18H15NO3

• Molecular Weight :

  293.32

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Ottonello L, et al. Delayed apoptosis of human monocytes exposed to immune complexes is reversed byoxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol. 2009 May;157 (2) :294-306.|[2]Montecucco F, et al. Oxaprozin-induced apoptosis on CD40 ligand-treated human primary monocytes is associated with the modulation of defined intracellular pathways. J Biomed Biotechnol. 2009;2009:478785.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  COX-1; COX-2; IKK; NF-κB